Cullinan Therapeutics to Present First Data for CLN-619, a :

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...

Related Keywords

Virginia , United States , Chad , Cambridge , Cambridgeshire , United Kingdom , American , Jeffrey Jones , Alexander Spira , Jeff Jones , Rose Weldon , American Society Of Clinical Oncology , Exchange Commission , Virginia Cancer Specialists Research Institute , Development Plan , Linkedin , Cullinan Therapeutics Inc , Nasdaq , Clinical Oncology , Annual Meeting , Key Clinical Results , Combination Arm , Combination Cohorts , Updated Key Clinical Results , Chief Medical Officer , Olive Investor , Investor Event , Cullinan Therapeutics , Chad Messer , Private Securities Litigation Reform Act , Annual Report ,